<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951649</url>
  </required_header>
  <id_info>
    <org_study_id>HA123456789</org_study_id>
    <nct_id>NCT03951649</nct_id>
  </id_info>
  <brief_title>Acute Headache Treatment in Pregnancy: Occipital Nerve Block vs PO Acetaminophen With Caffeine</brief_title>
  <official_title>Acute Headache Treatment in Pregnancy: Improvement in Pain Scores With Occipital Nerve Block vs PO Acetaminophen With Caffeine A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label randomized controlled trial evaluating response to bupivacaine
      occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients
      seeking care of headache.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label randomized controlled trial. Women who present to the MEU with headache
      will be assessed by trained nurse practitioners and/or OB/GYN residents. If the woman meets
      criteria for the study she will be enrolled by an MEU provider doing the primary assessment.

      See Figure 1 for the flow diagram depicting the patient's course through MEU. If eligible for
      inclusion, women will be randomly assigned to ONB or headache cocktail. Randomization will
      occur at time of enrollment. Prior to headache treatment 10-point visual/verbal rating scale
      (VRS) will be obtained. Treatment time is defined as time the patient takes the medication or
      the time that the needle is inserted into the greater occipital notch. At 60 min after
      treatment VRS will again be obtained by nursing staff or primary provider. If headache pain
      is resolved, defined as a VRS 0, the patient will be discharged to home (at the discretion of
      the managing team providing there are no other indications for further observation or
      admission). If pain continues to be present VRS will again be assessed at 120 min after
      treatment. If pain is not improved to mild range, defined as a VRS ≤ 3, or resolved,
      crossover treatment will be given. VRS will be obtained at 60 min after cross over treatment;
      if pain is resolved patient will be discharge to home. If pain continues to be present VRS
      will be obtained at 120 min after cross over treatment. If pain is not improved to mild pain
      or resolved; second line treatment of Promethazine 25mg/Benadryl 25mg will be given. VRS will
      again be obtained 60 min after second line treatment. If pain is not improved to mild pain
      (VRS ≤3) or resolved neurology consult will be considered. If at any point during treatment
      the patient develops new neurological symptoms study protocol will be stopped and neurology
      will be consulted.

      Patients will be called 7 days after discharge to access short term outcomes (headache
      frequency since MEU visit, injection site complications, and satisfaction with treatment.)
      Patients will again be called at 28 days and a chart abstraction will be done to access for
      long term outcomes (recurrent presentation for headache to the MEU, maternal complications
      including preeclampsia, or fetal complications).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled Trail</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to occipital nerve block in pregnancy</measure>
    <time_frame>60-300 min</time_frame>
    <description>Based on guidelines from the International Headache Society the primary outcome is the portion of women who experience resolution of headache or improvement of headache to mild range (VRS ≤ 3) at 2 hours following treatment with Occipital nerve block as compared to acetaminophen/caffeine cocktail.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to treatment within 2 hours</measure>
    <time_frame>2 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for crossover treatment</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to cross over treatment at 60 or 120 min</measure>
    <time_frame>60-120 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for second line treatment</measure>
    <time_frame>120 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to second line treatment at 60 min</measure>
    <time_frame>180min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for neurology consult</measure>
    <time_frame>5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for admission for treatment of headache</measure>
    <time_frame>7 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for representation for treatment of headache with 28 days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of hypertensive disease of pregnancy within 28 days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with response treatment at 7 days</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of headache free period at 7 days</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of hypertensive disease of pregnancy within 7 days</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection site complication (infection, hematoma, and ecchymosis)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Headache</condition>
  <condition>Pregnancy Related</condition>
  <condition>Occipital Nerve Block</condition>
  <arm_group>
    <arm_group_label>Occipital Nerve block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trained OB/GYN providers will perform a physical exam to access location of occipital nerve injection based on palpation of bony landmarks.
Site of injection will be cleaned with an alcohol swab.
5cc of 0.5% bupivacaine will be injected into both right and left occipital nerves using a 2.5 inch 25 gauge needle. The needle will be changed between injecting sites.
After injection is completed sterile gauze will be held on injection sites for 2-3 min or until bleeding is resolved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Acetaminophen/Caffeine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetaminophen 650mg PO and Caffeine 100mg PO (both Level A treatments for acute headache)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Occipital Nerve Block</intervention_name>
    <description>This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.</description>
    <arm_group_label>Occipital Nerve block</arm_group_label>
    <arm_group_label>Oral Acetaminophen/Caffeine Group</arm_group_label>
    <other_name>Acetaminophen/Caffeine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Women presenting to Maternal Evaluation Unit at UAB hospital

          2. Confirmed live intrauterine pregnancy (previous ultrasound, bedside ultrasound, fetal
             monitoring)

          3. Complaint of headache

          4. Minimal pain level of 4 on VRS

        Exclusion criteria:

          1. Systolic BP &gt;= 140 or diastolic BP&gt;=90 with 1+ protein on urine dip

          2. Systolic BP &gt;=160 or diastolic BP&gt;=105

          3. Focal neurological symptoms

          4. Altered level of consciousness defined as not being oriented to person, place,
             situation, and/or year

          5. Complaint of seizure

          6. Known under lying brain abnormality

          7. Fever

          8. Use of &gt;3 grams of acetaminophen in past 24hrs

          9. ONB in the past 3 months

         10. Reported allergy to study medications (Bupivacaine, acetaminophen, or caffeine)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant Females</gender_description>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elisa T Bushman, MD</last_name>
    <phone>205-934-9188</phone>
    <email>ebushman@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel G Sinkey, MD</last_name>
    <phone>(205) 934-5612</phone>
    <email>rsinkey@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Women and Infants center at the University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa T Bushman, MD</last_name>
      <phone>205-934-9788</phone>
      <email>ebushman@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rachael G Sinkey, MD</last_name>
      <phone>(205) 934-5612</phone>
      <email>rsinkey@uabmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population--a prevalence study. J Clin Epidemiol. 1991;44(11):1147-57.</citation>
    <PMID>1941010</PMID>
  </results_reference>
  <results_reference>
    <citation>Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30;68(5):343-9.</citation>
    <PMID>17261680</PMID>
  </results_reference>
  <results_reference>
    <citation>Scharff L, Marcus DA, Turk DC. Headache during pregnancy and in the postpartum: a prospective study. Headache. 1997 Apr;37(4):203-10.</citation>
    <PMID>9150614</PMID>
  </results_reference>
  <results_reference>
    <citation>Bushman ET, Varner MW, Digre KB. Headaches Through a Woman's Life. Obstet Gynecol Surv. 2018 Mar;73(3):161-173. doi: 10.1097/OGX.0000000000000540. Review.</citation>
    <PMID>29595872</PMID>
  </results_reference>
  <results_reference>
    <citation>Robbins MS, Farmakidis C, Dayal AK, Lipton RB. Acute headache diagnosis in pregnant women: a hospital-based study. Neurology. 2015 Sep 22;85(12):1024-30. doi: 10.1212/WNL.0000000000001954. Epub 2015 Aug 19.</citation>
    <PMID>26291282</PMID>
  </results_reference>
  <results_reference>
    <citation>Loder E, Biondi D. General principles of migraine management: the changing role of prevention. Headache. 2005 Apr;45 Suppl 1:S33-47. Review.</citation>
    <PMID>15833089</PMID>
  </results_reference>
  <results_reference>
    <citation>Cuadrado ML, Aledo-Serrano Á, Navarro P, López-Ruiz P, Fernández-de-Las-Peñas C, González-Suárez I, Orviz A, Fernández-Pérez C. Short-term effects of greater occipital nerve blocks in chronic migraine: A double-blind, randomised, placebo-controlled clinical trial. Cephalalgia. 2017 Aug;37(9):864-872. doi: 10.1177/0333102416655159. Epub 2016 Jun 12.</citation>
    <PMID>27296456</PMID>
  </results_reference>
  <results_reference>
    <citation>Dach F, Éckeli ÁL, Ferreira Kdos S, Speciali JG. Nerve block for the treatment of headaches and cranial neuralgias - a practical approach. Headache. 2015 Feb;55 Suppl 1:59-71. doi: 10.1111/head.12516. Epub 2015 Feb 3. Review.</citation>
    <PMID>25644836</PMID>
  </results_reference>
  <results_reference>
    <citation>Gul HL, Ozon AO, Karadas O, Koc G, Inan LE. The efficacy of greater occipital nerve blockade in chronic migraine: A placebo-controlled study. Acta Neurol Scand. 2017 Aug;136(2):138-144. doi: 10.1111/ane.12716. Epub 2016 Dec 2.</citation>
    <PMID>27910088</PMID>
  </results_reference>
  <results_reference>
    <citation>Hascalovici JR, Robbins MS. Peripheral Nerve Blocks for the Treatment of Headache in Older Adults: A Retrospective Study. Headache. 2017 Jan;57(1):80-86. doi: 10.1111/head.12992. Epub 2016 Nov 30.</citation>
    <PMID>27901275</PMID>
  </results_reference>
  <results_reference>
    <citation>Tang Y, Kang J, Zhang Y, Zhang X. Influence of greater occipital nerve block on pain severity in migraine patients: A systematic review and meta-analysis. Am J Emerg Med. 2017 Nov;35(11):1750-1754. doi: 10.1016/j.ajem.2017.08.027. Epub 2017 Aug 14. Review.</citation>
    <PMID>28844531</PMID>
  </results_reference>
  <results_reference>
    <citation>Tobin J, Flitman S. Occipital nerve blocks: when and what to inject? Headache. 2009 Nov-Dec;49(10):1521-33. doi: 10.1111/j.1526-4610.2009.01493.x. Epub 2009 Aug 6. Review.</citation>
    <PMID>19674126</PMID>
  </results_reference>
  <results_reference>
    <citation>Blumenfeld A, Ashkenazi A, Napchan U, Bender SD, Klein BC, Berliner R, Ailani J, Schim J, Friedman DI, Charleston L 4th, Young WB, Robertson CE, Dodick DW, Silberstein SD, Robbins MS. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches--a narrative review. Headache. 2013 Mar;53(3):437-46. doi: 10.1111/head.12053. Epub 2013 Feb 13. Review.</citation>
    <PMID>23406160</PMID>
  </results_reference>
  <results_reference>
    <citation>Voigt CL, Murphy MO. Occipital nerve blocks in the treatment of headaches: safety and efficacy. J Emerg Med. 2015 Jan;48(1):115-29. doi: 10.1016/j.jemermed.2014.09.007. Epub 2014 Oct 18. Review.</citation>
    <PMID>25440865</PMID>
  </results_reference>
  <results_reference>
    <citation>Govindappagari S, Grossman TB, Dayal AK, Grosberg BM, Vollbracht S, Robbins MS. Peripheral nerve blocks in the treatment of migraine in pregnancy. Obstet Gynecol. 2014 Dec;124(6):1169-74. doi: 10.1097/AOG.0000000000000555.</citation>
    <PMID>25415168</PMID>
  </results_reference>
  <results_reference>
    <citation>Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med. 2000 Dec 11-25;160(22):3486-92.</citation>
    <PMID>11112243</PMID>
  </results_reference>
  <results_reference>
    <citation>Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499. Review.</citation>
    <PMID>25600718</PMID>
  </results_reference>
  <results_reference>
    <citation>James AH, Brancazio LR, Price T. Aspirin and reproductive outcomes. Obstet Gynecol Surv. 2008 Jan;63(1):49-57. Review.</citation>
    <PMID>18081940</PMID>
  </results_reference>
  <results_reference>
    <citation>Korucu O, Dagar S, Çorbacioglu ŞK, Emektar E, Cevik Y. The effectiveness of greater occipital nerve blockade in treating acute migraine-related headaches in emergency departments. Acta Neurol Scand. 2018 Sep;138(3):212-218. doi: 10.1111/ane.12952. Epub 2018 May 10.</citation>
    <PMID>29744871</PMID>
  </results_reference>
  <results_reference>
    <citation>Allen SM, Mookadam F, Cha SS, Freeman JA, Starling AJ, Mookadam M. Greater Occipital Nerve Block for Acute Treatment of Migraine Headache: A Large Retrospective Cohort Study. J Am Board Fam Med. 2018 Mar-Apr;31(2):211-218. doi: 10.3122/jabfm.2018.02.170188.</citation>
    <PMID>29535237</PMID>
  </results_reference>
  <results_reference>
    <citation>Negro A, Delaruelle Z, Ivanova TA, Khan S, Ornello R, Raffaelli B, Terrin A, Reuter U, Mitsikostas DD; European Headache Federation School of Advanced Studies (EHF-SAS). Headache and pregnancy: a systematic review. J Headache Pain. 2017 Oct 19;18(1):106. doi: 10.1186/s10194-017-0816-0. Review.</citation>
    <PMID>29052046</PMID>
  </results_reference>
  <results_reference>
    <citation>Schoen JC, Campbell RL, Sadosty AT. Headache in pregnancy: an approach to emergency department evaluation and management. West J Emerg Med. 2015 Mar;16(2):291-301. doi: 10.5811/westjem.2015.1.23688. Epub 2015 Feb 25. Review.</citation>
    <PMID>25834672</PMID>
  </results_reference>
  <results_reference>
    <citation>Lipton RB, Diener HC, Robbins MS, Garas SY, Patel K. Caffeine in the management of patients with headache. J Headache Pain. 2017 Oct 24;18(1):107. doi: 10.1186/s10194-017-0806-2. Review.</citation>
    <PMID>29067618</PMID>
  </results_reference>
  <results_reference>
    <citation>Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J; International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia. 2019 May;39(6):687-710. doi: 10.1177/0333102419828967. Epub 2019 Feb 26.</citation>
    <PMID>30806518</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Elisa T Bushman</investigator_full_name>
    <investigator_title>Fellow/Instructor</investigator_title>
  </responsible_party>
  <keyword>headache</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Acute treatment</keyword>
  <keyword>Emergency department</keyword>
  <keyword>Occipital nerve block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

